The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Biologic Medication in COVID-19 Market Research Report 2025
Synopsis
According to China's clinical trials of COVID-19 treatment, the number of chemical drugs accounted for the highest proportion, followed by biological drugs, cell therapy, vaccines, and traditional Chinese medicine. Among the biological drugs, IL-6 related monoclonal antibodies (anti-inflammatory) account for the largest proportion, including tocilizumab and Sarilumab. This report focuses on the investigation and analysis of biologic medication and predicts the future market development of biopharmaceuticals under the influence of COVID-19. Biological drugs are mainly divided into two categories: neutralizing antibodies and anti-inflammatory drugs. The main subdivisions include: IL-6, C5a, CD147, PD-1 and Interferon (beta-1a), etc.
The global Biologic Medication in COVID-19 market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Biologic Medication in COVID-19, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biologic Medication in COVID-19.
Report Scope
The Biologic Medication in COVID-19 market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biologic Medication in COVID-19 market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biologic Medication in COVID-19 companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Sanofi
Novartis
Merck
Bayer
Shutaishen
Biogen
Regeneron Pharmaceuticals
Vir Biotech
Junshi Biosciences
Anke Biotechnology
OncoImmune
Segment by Type
Neutralizing Antibodies
Anti-inflammatory Drugs
Segment by Application
COVID-19
Influenza
Malaria
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biologic Medication in COVID-19 companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
According to China's clinical trials of COVID-19 treatment, the number of chemical drugs accounted for the highest proportion, followed by biological drugs, cell therapy, vaccines, and traditional Chinese medicine. Among the biological drugs, IL-6 related monoclonal antibodies (anti-inflammatory) account for the largest proportion, including tocilizumab and Sarilumab. This report focuses on the investigation and analysis of biologic medication and predicts the future market development of biopharmaceuticals under the influence of COVID-19. Biological drugs are mainly divided into two categories: neutralizing antibodies and anti-inflammatory drugs. The main subdivisions include: IL-6, C5a, CD147, PD-1 and Interferon (beta-1a), etc.
The global Biologic Medication in COVID-19 market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Biologic Medication in COVID-19, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biologic Medication in COVID-19.
Report Scope
The Biologic Medication in COVID-19 market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biologic Medication in COVID-19 market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biologic Medication in COVID-19 companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Sanofi
Novartis
Merck
Bayer
Shutaishen
Biogen
Regeneron Pharmaceuticals
Vir Biotech
Junshi Biosciences
Anke Biotechnology
OncoImmune
Segment by Type
Neutralizing Antibodies
Anti-inflammatory Drugs
Segment by Application
COVID-19
Influenza
Malaria
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biologic Medication in COVID-19 companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Biologic Medication in COVID-19 Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Neutralizing Antibodies
1.2.3 Anti-inflammatory Drugs
1.3 Market by Application
1.3.1 Global Biologic Medication in COVID-19 Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 COVID-19
1.3.3 Influenza
1.3.4 Malaria
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biologic Medication in COVID-19 Market Perspective (2019-2030)
2.2 Biologic Medication in COVID-19 Growth Trends by Region
2.2.1 Global Biologic Medication in COVID-19 Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Biologic Medication in COVID-19 Historic Market Size by Region (2019-2024)
2.2.3 Biologic Medication in COVID-19 Forecasted Market Size by Region (2025-2030)
2.3 Biologic Medication in COVID-19 Market Dynamics
2.3.1 Biologic Medication in COVID-19 Industry Trends
2.3.2 Biologic Medication in COVID-19 Market Drivers
2.3.3 Biologic Medication in COVID-19 Market Challenges
2.3.4 Biologic Medication in COVID-19 Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Biologic Medication in COVID-19 Players by Revenue
3.1.1 Global Top Biologic Medication in COVID-19 Players by Revenue (2019-2024)
3.1.2 Global Biologic Medication in COVID-19 Revenue Market Share by Players (2019-2024)
3.2 Global Biologic Medication in COVID-19 Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Biologic Medication in COVID-19 Revenue
3.4 Global Biologic Medication in COVID-19 Market Concentration Ratio
3.4.1 Global Biologic Medication in COVID-19 Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biologic Medication in COVID-19 Revenue in 2023
3.5 Biologic Medication in COVID-19 Key Players Head office and Area Served
3.6 Key Players Biologic Medication in COVID-19 Product Solution and Service
3.7 Date of Enter into Biologic Medication in COVID-19 Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Biologic Medication in COVID-19 Breakdown Data by Type
4.1 Global Biologic Medication in COVID-19 Historic Market Size by Type (2019-2024)
4.2 Global Biologic Medication in COVID-19 Forecasted Market Size by Type (2025-2030)
5 Biologic Medication in COVID-19 Breakdown Data by Application
5.1 Global Biologic Medication in COVID-19 Historic Market Size by Application (2019-2024)
5.2 Global Biologic Medication in COVID-19 Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Biologic Medication in COVID-19 Market Size (2019-2030)
6.2 North America Biologic Medication in COVID-19 Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Biologic Medication in COVID-19 Market Size by Country (2019-2024)
6.4 North America Biologic Medication in COVID-19 Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Biologic Medication in COVID-19 Market Size (2019-2030)
7.2 Europe Biologic Medication in COVID-19 Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Biologic Medication in COVID-19 Market Size by Country (2019-2024)
7.4 Europe Biologic Medication in COVID-19 Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Biologic Medication in COVID-19 Market Size (2019-2030)
8.2 Asia-Pacific Biologic Medication in COVID-19 Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Biologic Medication in COVID-19 Market Size by Region (2019-2024)
8.4 Asia-Pacific Biologic Medication in COVID-19 Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Biologic Medication in COVID-19 Market Size (2019-2030)
9.2 Latin America Biologic Medication in COVID-19 Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Biologic Medication in COVID-19 Market Size by Country (2019-2024)
9.4 Latin America Biologic Medication in COVID-19 Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Biologic Medication in COVID-19 Market Size (2019-2030)
10.2 Middle East & Africa Biologic Medication in COVID-19 Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Biologic Medication in COVID-19 Market Size by Country (2019-2024)
10.4 Middle East & Africa Biologic Medication in COVID-19 Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Biologic Medication in COVID-19 Introduction
11.1.4 Roche Revenue in Biologic Medication in COVID-19 Business (2019-2024)
11.1.5 Roche Recent Development
11.2 Sanofi
11.2.1 Sanofi Company Detail
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Biologic Medication in COVID-19 Introduction
11.2.4 Sanofi Revenue in Biologic Medication in COVID-19 Business (2019-2024)
11.2.5 Sanofi Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Biologic Medication in COVID-19 Introduction
11.3.4 Novartis Revenue in Biologic Medication in COVID-19 Business (2019-2024)
11.3.5 Novartis Recent Development
11.4 Merck
11.4.1 Merck Company Detail
11.4.2 Merck Business Overview
11.4.3 Merck Biologic Medication in COVID-19 Introduction
11.4.4 Merck Revenue in Biologic Medication in COVID-19 Business (2019-2024)
11.4.5 Merck Recent Development
11.5 Bayer
11.5.1 Bayer Company Detail
11.5.2 Bayer Business Overview
11.5.3 Bayer Biologic Medication in COVID-19 Introduction
11.5.4 Bayer Revenue in Biologic Medication in COVID-19 Business (2019-2024)
11.5.5 Bayer Recent Development
11.6 Shutaishen
11.6.1 Shutaishen Company Detail
11.6.2 Shutaishen Business Overview
11.6.3 Shutaishen Biologic Medication in COVID-19 Introduction
11.6.4 Shutaishen Revenue in Biologic Medication in COVID-19 Business (2019-2024)
11.6.5 Shutaishen Recent Development
11.7 Biogen
11.7.1 Biogen Company Detail
11.7.2 Biogen Business Overview
11.7.3 Biogen Biologic Medication in COVID-19 Introduction
11.7.4 Biogen Revenue in Biologic Medication in COVID-19 Business (2019-2024)
11.7.5 Biogen Recent Development
11.8 Regeneron Pharmaceuticals
11.8.1 Regeneron Pharmaceuticals Company Detail
11.8.2 Regeneron Pharmaceuticals Business Overview
11.8.3 Regeneron Pharmaceuticals Biologic Medication in COVID-19 Introduction
11.8.4 Regeneron Pharmaceuticals Revenue in Biologic Medication in COVID-19 Business (2019-2024)
11.8.5 Regeneron Pharmaceuticals Recent Development
11.9 Vir Biotech
11.9.1 Vir Biotech Company Detail
11.9.2 Vir Biotech Business Overview
11.9.3 Vir Biotech Biologic Medication in COVID-19 Introduction
11.9.4 Vir Biotech Revenue in Biologic Medication in COVID-19 Business (2019-2024)
11.9.5 Vir Biotech Recent Development
11.10 Junshi Biosciences
11.10.1 Junshi Biosciences Company Detail
11.10.2 Junshi Biosciences Business Overview
11.10.3 Junshi Biosciences Biologic Medication in COVID-19 Introduction
11.10.4 Junshi Biosciences Revenue in Biologic Medication in COVID-19 Business (2019-2024)
11.10.5 Junshi Biosciences Recent Development
11.11 Anke Biotechnology
11.11.1 Anke Biotechnology Company Detail
11.11.2 Anke Biotechnology Business Overview
11.11.3 Anke Biotechnology Biologic Medication in COVID-19 Introduction
11.11.4 Anke Biotechnology Revenue in Biologic Medication in COVID-19 Business (2019-2024)
11.11.5 Anke Biotechnology Recent Development
11.12 OncoImmune
11.12.1 OncoImmune Company Detail
11.12.2 OncoImmune Business Overview
11.12.3 OncoImmune Biologic Medication in COVID-19 Introduction
11.12.4 OncoImmune Revenue in Biologic Medication in COVID-19 Business (2019-2024)
11.12.5 OncoImmune Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Biologic Medication in COVID-19 Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Neutralizing Antibodies
Table 3. Key Players of Anti-inflammatory Drugs
Table 4. Global Biologic Medication in COVID-19 Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Biologic Medication in COVID-19 Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Biologic Medication in COVID-19 Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Biologic Medication in COVID-19 Market Share by Region (2019-2024)
Table 8. Global Biologic Medication in COVID-19 Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Biologic Medication in COVID-19 Market Share by Region (2025-2030)
Table 10. Biologic Medication in COVID-19 Market Trends
Table 11. Biologic Medication in COVID-19 Market Drivers
Table 12. Biologic Medication in COVID-19 Market Challenges
Table 13. Biologic Medication in COVID-19 Market Restraints
Table 14. Global Biologic Medication in COVID-19 Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Biologic Medication in COVID-19 Market Share by Players (2019-2024)
Table 16. Global Top Biologic Medication in COVID-19 Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biologic Medication in COVID-19 as of 2023)
Table 17. Ranking of Global Top Biologic Medication in COVID-19 Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Biologic Medication in COVID-19 Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Biologic Medication in COVID-19 Product Solution and Service
Table 21. Date of Enter into Biologic Medication in COVID-19 Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Biologic Medication in COVID-19 Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Biologic Medication in COVID-19 Revenue Market Share by Type (2019-2024)
Table 25. Global Biologic Medication in COVID-19 Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Biologic Medication in COVID-19 Revenue Market Share by Type (2025-2030)
Table 27. Global Biologic Medication in COVID-19 Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Biologic Medication in COVID-19 Revenue Market Share by Application (2019-2024)
Table 29. Global Biologic Medication in COVID-19 Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Biologic Medication in COVID-19 Revenue Market Share by Application (2025-2030)
Table 31. North America Biologic Medication in COVID-19 Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Biologic Medication in COVID-19 Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Biologic Medication in COVID-19 Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Biologic Medication in COVID-19 Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Biologic Medication in COVID-19 Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Biologic Medication in COVID-19 Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Biologic Medication in COVID-19 Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Biologic Medication in COVID-19 Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Biologic Medication in COVID-19 Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Biologic Medication in COVID-19 Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Biologic Medication in COVID-19 Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Biologic Medication in COVID-19 Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Biologic Medication in COVID-19 Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Biologic Medication in COVID-19 Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Biologic Medication in COVID-19 Market Size by Country (2025-2030) & (US$ Million)
Table 46. Roche Company Detail
Table 47. Roche Business Overview
Table 48. Roche Biologic Medication in COVID-19 Product
Table 49. Roche Revenue in Biologic Medication in COVID-19 Business (2019-2024) & (US$ Million)
Table 50. Roche Recent Development
Table 51. Sanofi Company Detail
Table 52. Sanofi Business Overview
Table 53. Sanofi Biologic Medication in COVID-19 Product
Table 54. Sanofi Revenue in Biologic Medication in COVID-19 Business (2019-2024) & (US$ Million)
Table 55. Sanofi Recent Development
Table 56. Novartis Company Detail
Table 57. Novartis Business Overview
Table 58. Novartis Biologic Medication in COVID-19 Product
Table 59. Novartis Revenue in Biologic Medication in COVID-19 Business (2019-2024) & (US$ Million)
Table 60. Novartis Recent Development
Table 61. Merck Company Detail
Table 62. Merck Business Overview
Table 63. Merck Biologic Medication in COVID-19 Product
Table 64. Merck Revenue in Biologic Medication in COVID-19 Business (2019-2024) & (US$ Million)
Table 65. Merck Recent Development
Table 66. Bayer Company Detail
Table 67. Bayer Business Overview
Table 68. Bayer Biologic Medication in COVID-19 Product
Table 69. Bayer Revenue in Biologic Medication in COVID-19 Business (2019-2024) & (US$ Million)
Table 70. Bayer Recent Development
Table 71. Shutaishen Company Detail
Table 72. Shutaishen Business Overview
Table 73. Shutaishen Biologic Medication in COVID-19 Product
Table 74. Shutaishen Revenue in Biologic Medication in COVID-19 Business (2019-2024) & (US$ Million)
Table 75. Shutaishen Recent Development
Table 76. Biogen Company Detail
Table 77. Biogen Business Overview
Table 78. Biogen Biologic Medication in COVID-19 Product
Table 79. Biogen Revenue in Biologic Medication in COVID-19 Business (2019-2024) & (US$ Million)
Table 80. Biogen Recent Development
Table 81. Regeneron Pharmaceuticals Company Detail
Table 82. Regeneron Pharmaceuticals Business Overview
Table 83. Regeneron Pharmaceuticals Biologic Medication in COVID-19 Product
Table 84. Regeneron Pharmaceuticals Revenue in Biologic Medication in COVID-19 Business (2019-2024) & (US$ Million)
Table 85. Regeneron Pharmaceuticals Recent Development
Table 86. Vir Biotech Company Detail
Table 87. Vir Biotech Business Overview
Table 88. Vir Biotech Biologic Medication in COVID-19 Product
Table 89. Vir Biotech Revenue in Biologic Medication in COVID-19 Business (2019-2024) & (US$ Million)
Table 90. Vir Biotech Recent Development
Table 91. Junshi Biosciences Company Detail
Table 92. Junshi Biosciences Business Overview
Table 93. Junshi Biosciences Biologic Medication in COVID-19 Product
Table 94. Junshi Biosciences Revenue in Biologic Medication in COVID-19 Business (2019-2024) & (US$ Million)
Table 95. Junshi Biosciences Recent Development
Table 96. Anke Biotechnology Company Detail
Table 97. Anke Biotechnology Business Overview
Table 98. Anke Biotechnology Biologic Medication in COVID-19 Product
Table 99. Anke Biotechnology Revenue in Biologic Medication in COVID-19 Business (2019-2024) & (US$ Million)
Table 100. Anke Biotechnology Recent Development
Table 101. OncoImmune Company Detail
Table 102. OncoImmune Business Overview
Table 103. OncoImmune Biologic Medication in COVID-19 Product
Table 104. OncoImmune Revenue in Biologic Medication in COVID-19 Business (2019-2024) & (US$ Million)
Table 105. OncoImmune Recent Development
Table 106. Research Programs/Design for This Report
Table 107. Key Data Information from Secondary Sources
Table 108. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Biologic Medication in COVID-19 Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Biologic Medication in COVID-19 Market Share by Type: 2023 VS 2030
Figure 3. Neutralizing Antibodies Features
Figure 4. Anti-inflammatory Drugs Features
Figure 5. Global Biologic Medication in COVID-19 Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Biologic Medication in COVID-19 Market Share by Application: 2023 VS 2030
Figure 7. COVID-19 Case Studies
Figure 8. Influenza Case Studies
Figure 9. Malaria Case Studies
Figure 10. Others Case Studies
Figure 11. Biologic Medication in COVID-19 Report Years Considered
Figure 12. Global Biologic Medication in COVID-19 Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global Biologic Medication in COVID-19 Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Biologic Medication in COVID-19 Market Share by Region: 2023 VS 2030
Figure 15. Global Biologic Medication in COVID-19 Market Share by Players in 2023
Figure 16. Global Top Biologic Medication in COVID-19 Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biologic Medication in COVID-19 as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by Biologic Medication in COVID-19 Revenue in 2023
Figure 18. North America Biologic Medication in COVID-19 Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America Biologic Medication in COVID-19 Market Share by Country (2019-2030)
Figure 20. United States Biologic Medication in COVID-19 Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada Biologic Medication in COVID-19 Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Biologic Medication in COVID-19 Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Biologic Medication in COVID-19 Market Share by Country (2019-2030)
Figure 24. Germany Biologic Medication in COVID-19 Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France Biologic Medication in COVID-19 Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. Biologic Medication in COVID-19 Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy Biologic Medication in COVID-19 Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia Biologic Medication in COVID-19 Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries Biologic Medication in COVID-19 Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Biologic Medication in COVID-19 Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Biologic Medication in COVID-19 Market Share by Region (2019-2030)
Figure 32. China Biologic Medication in COVID-19 Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan Biologic Medication in COVID-19 Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea Biologic Medication in COVID-19 Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia Biologic Medication in COVID-19 Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India Biologic Medication in COVID-19 Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia Biologic Medication in COVID-19 Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Biologic Medication in COVID-19 Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Biologic Medication in COVID-19 Market Share by Country (2019-2030)
Figure 40. Mexico Biologic Medication in COVID-19 Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil Biologic Medication in COVID-19 Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Biologic Medication in COVID-19 Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Biologic Medication in COVID-19 Market Share by Country (2019-2030)
Figure 44. Turkey Biologic Medication in COVID-19 Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia Biologic Medication in COVID-19 Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Roche Revenue Growth Rate in Biologic Medication in COVID-19 Business (2019-2024)
Figure 47. Sanofi Revenue Growth Rate in Biologic Medication in COVID-19 Business (2019-2024)
Figure 48. Novartis Revenue Growth Rate in Biologic Medication in COVID-19 Business (2019-2024)
Figure 49. Merck Revenue Growth Rate in Biologic Medication in COVID-19 Business (2019-2024)
Figure 50. Bayer Revenue Growth Rate in Biologic Medication in COVID-19 Business (2019-2024)
Figure 51. Shutaishen Revenue Growth Rate in Biologic Medication in COVID-19 Business (2019-2024)
Figure 52. Biogen Revenue Growth Rate in Biologic Medication in COVID-19 Business (2019-2024)
Figure 53. Regeneron Pharmaceuticals Revenue Growth Rate in Biologic Medication in COVID-19 Business (2019-2024)
Figure 54. Vir Biotech Revenue Growth Rate in Biologic Medication in COVID-19 Business (2019-2024)
Figure 55. Junshi Biosciences Revenue Growth Rate in Biologic Medication in COVID-19 Business (2019-2024)
Figure 56. Anke Biotechnology Revenue Growth Rate in Biologic Medication in COVID-19 Business (2019-2024)
Figure 57. OncoImmune Revenue Growth Rate in Biologic Medication in COVID-19 Business (2019-2024)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
